Isolated Cranial Nerve 6 Palsy in 6 Patients With COVID-19 Infection
Taking a Strohl Through History: Putting Strohl Back in Guillain-Barre-Strohl Syndrome [Meeting Abstract]
Taking a Strohl Through History: Putting Strohl Back in Guillain-BarrÃ©-Strohl Syndrome
Guillain-BarrÃ© Syndrome is a popular eponym that comes from a 1916 paper by Drs. Guillain, BarrÃ©, and Strohl. These physicians described two soldiers in the French Sixth Army during World War I who developed acute progressive motor weakness. Although Drs. Guillain and BarrÃ© have continued to be included in the syndrome's eponym, Dr. Strohl has been forgotten despite having strongly contributed to the original paper. The reasons previously mentioned for Dr. Strohl's absence appear trivial in contemporary practice and thus, his name deserves to be reintroduced to Guillain-BarrÃ©-Strohl Syndrome.
Xpert MTB/RIF Ultra for Detection of Mycobacterium tuberculosis in Cerebrospinal Fluid [Letter]
Hypertension-A Global Neurological Problem
The Epidemiology of Neuromuscular Diseases
Neuromuscular disorders as a group are linked by anatomy with significant differences in pathogenetic mechanisms, clinical expression, and time course of disease. Each neuromuscular disease is relatively uncommon, yet causes a significant burden of disease socioeconomically. Epidemiologic studies in different global regions have demonstrated certain neuromuscular diseases have increased incidence and prevalence rates over time. Understanding differences in global epidemiologic trends will aid clinical research and policies focused on prevention of disease. There is a critical need to understand the global impact of neuromuscular diseases using metrics currently established for communicable and noncommunicable diseases.
Fragile X Tremor Ataxia Syndrome With Rapidly Progressive Myopathy
Singultus as a sequelae of lateral medullary infarction: Rehabilitation perspective. A case report
Hiccups are a rare manifestation of Lateral Medullary Infarction (LMI). Strokes produce numerous complications, hiccup manifestations are limited in reviewing literatures. Diagnoses of LMIs have been documented predominately by use of MRIs. There have been attempts to make clinical with MRI correlations in patients with LMI, studies with a large number of patients are uncommon among subjects with this etiology. Previous literatures have attempted to investigate anatomical lesions in patients with LMI suffering from hiccups by using imaging. Initial signs are usually headache, vertigo, dizziness or gait ataxia, whereas sensory symptoms consisting of dysphagia, hoarseness and hiccups usually occurred in the latter aspect. Hiccups in LMI are not fully understood and has been insufficiently studied. We describe a case of a man in his sixties with a constant occipital headache lasting 12 days associated with nausea and vomiting prior to admission to acute hospital. There was no history of exposure to any prescription or recreational drugs prior to presentation. The day after admission, he presented with intractable hiccups. Treatment with chlorpromazine (Thorazine) was unsuccessful, hiccups improved after initiation of baclofen and physical therapy. This case suggests that physical therapy may be a valuable aspect for refractory hiccups in conjunction with pharmacological management
Amyotrophic lateral sclerosis (ALS)
Berlin: Elsevier, 2010
Current clinical trials in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is caused by selective degeneration of motor neurons in the brain and spinal cord. There are still no other effective therapies 10 years after the approval of riluzole for the treatment of amyotrophic lateral sclerosis, but advances in drug development and screening are substantially increasing the number of potential therapeutic agents. This review provides an overview of clinical trial methodology in amyotrophic lateral sclerosis followed by a systematic evaluation of drugs that are presently in Phase I, II and III clinical trials. There is an emphasis on the scientific evidence supporting the selection of each drug being tested, as well as on trial design